Rocket Medical Plc Launches HyView® HSG and HyCoSy Catheter for Improved Fertility Outcomes in Women
WASHINGTON, UK (26 February, 2025) – Rocket Medical Plc, a leading global designer, manufacturer, and distributor of medical devices, has announced the launch of its new product, the HyView HSG and HyCoSy Catheter. Developed specifically for use in hysterosalpingography (HSG) and Hysterosalpingo Contrast Sonography (HyCoSy) procedures, the new device aims to improve fertility outcomes for women.
The procedure involves the use of an imaging medium that is instilled through the catheter to visualize the shape of the uterus and assess the patency of the fallopian tubes in real time, using either fluoroscopy (HSG) or ultrasound (HyCoSy). While water-based media has traditionally been used, Rocket Medical Plc’s new device allows for the use of Lipiodol® Ultra Fluid, an oil-based contrast, which has been found to have potential benefits for fertility outcomes1-5.
Research has shown that the use of Lipiodol in HSG may increase pregnancy and live birth rates compared to the use of water-based contrast medium1-3. It has also been suggested that there may be benefits for patients with endometriosis, as a New Zealand randomized trial showed enhanced fertility for up to 6 months following a Lipiodol flush, and for a longer period in women with unexplained infertility1,4,5.
However, there are limited suitable options for catheters when Lipiodol is used, as many are damaged after a short period of contact. The HyView catheter has been extensively tested for reliability and integrity and can be used with Lipiodol for up to 60 minutes, making it a dependable device for more complex cases.
Daniel J. Agustus, PhD., Managing Director at Rocket Medical Plc, expressed excitement about the potential impact of the new device. He stated, “Research has shown the important role that Lipiodol HSG may have in managing patients seeking medical assistance for infertility. The HyView catheter extends our existing HSG and HyCoSy catheter portfolio with a Lipiodol-resistant device, ensuring that we continue to meet the evolving needs of clinicians.”
The HyView catheter is currently available in the UK, Ireland, the Netherlands, Australia, and New Zealand, with plans for further market expansion. The device is available in 5FG without a stylet and 5FG with a stylet, which may be useful for difficult insertions.
For more information on the HyView HSG and HyCoSy Catheter, please visit www.rocketmedical.com or contact customerservices@rocketmedical.com.
About Rocket Medical Plc
Rocket Medical Plc is a global designer, manufacturer, and distributor of medical devices, specializing in Women’s Health and Drainage. The company is dedicated to providing innovative and high-quality medical solutions to improve patient outcomes.
Media Contact:
Rocket Medical Plc.
Email: marketing@rocketmedical.com
www.rocketmedical.com
References:
1. https://womenshealth.guerbet.com/products/lipiodol-ultra-fluid, accessed 20 February, 2025
2. Wang, R., van Welie, N., van Rijswijk, J., Johnson, N. P., Norman, R. J., Dreyer, K., Mijatovic, V., & Mol, B. W. (2019). Effectiveness on fertility outcome of tubal flushing with different contrast media: systematic review and network meta-analysis. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 54(2), 172–181. https://doi.org/10.1002/uog.20238
3. Dreyer, K., van Rijswijk, J., Mijatovic, V., Goddijn, M., Verhoeve, H. R., van Rooij, I. A. J., Hoek, A., Bourdrez, P., Nap, A. W., Rijnsaardt-Lukassen, H. G. M., Timmerman, C. C. M., Kaplan, M., Hooker, A. B., Gijsen, A. P., van Golde, R., van Heteren, C. F., Sluijmer, A. V., de Bruin, J. P., Smeenk, J. M. J., de Boer, J. A. M., … Mol, B. W. J. (2017). Oil-Based or Water-Based Contrast for Hysterosalpingography in Infertile Women. The New England journal of medicine, 376(21
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.